EP1214094A1 - Utilisation de savons d'acide gras ou d'acide amine pour ameliorer l'efficacite anti-microbienne de compositions pharmaceutiques topiques - Google Patents

Utilisation de savons d'acide gras ou d'acide amine pour ameliorer l'efficacite anti-microbienne de compositions pharmaceutiques topiques

Info

Publication number
EP1214094A1
EP1214094A1 EP00961722A EP00961722A EP1214094A1 EP 1214094 A1 EP1214094 A1 EP 1214094A1 EP 00961722 A EP00961722 A EP 00961722A EP 00961722 A EP00961722 A EP 00961722A EP 1214094 A1 EP1214094 A1 EP 1214094A1
Authority
EP
European Patent Office
Prior art keywords
fatty acid
amino acid
agents
antimicrobial
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00961722A
Other languages
German (de)
English (en)
Inventor
Ernesto J. Castillo
Steven Howard Gerson
Wesley Wehsin Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of EP1214094A1 publication Critical patent/EP1214094A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Definitions

  • the present invention relates generally to the preservation of pharmaceutical compositions.
  • the present invention relates to the use of fatty acid/amino acid soaps to prevent or to reduce binding of the antimicrobial components of topically administrable pharmaceutical compositions to other components contained therein, thereby improving the antimicrobial efficacy of such compositions.
  • ophthalmic compositions that contain a variety of components, such as carboxyvinyl polymers (e.g., Carbopol ® ), ion exchange resins (e.g., Amberlite ® ), or other large polyelectrolytes, which provide sustained release of the ophthalmic agent(s), as well as increased patient comfort.
  • carboxyvinyl polymers e.g., Carbopol ®
  • ion exchange resins e.g., Amberlite ®
  • Such compositions are described, for example, in US 4,911 ,920 (Jani et al.).
  • compositions are comfortable and have sustained release characteristics, cationic antimicrobials, such as benzalkonium chloride (BAC), which are often added as preservatives to such compositions, tend to bind to the anionic polyelectrolytes present in the formulations, resulting in loss of antimicrobial effectiveness.
  • BAC benzalkonium chloride
  • Sarcosinate surfactants are composed of acylated sarcosines.
  • Sarcosine (CH 3 -NH-CH 2 -COOH), an amino acid normally found in starfish and sea urchins, is chemically related to glycine (NH 2 -CH 2 -COOH), a basic amino acid in mammals.
  • Common fatty acids and their derivatives utilized in the manufacture of sarcosinate surfactants are lauric, oleic, and myristic acids and their esters and halides. Because of their mildness, sarcosinate surfactants have been utilized in shampoos, mouthwashes, skin cleansers, sunscreens, aerosol shaving lathers and other personal care products. To date, the main applications of these types of surfactants have been in the cosmetic industry.
  • European Patent Application No. 0 194 097 (Schmidt et al.), assigned to Procter & Gamble, mentions sodium lauroyl sarcosinate as the mild anionic surfactant utilized in an aerosol skin-cleansing and moisturizer mousse.
  • U.S. Patent No. 5,520,920 (Castillo, et al.) discloses the use of certain modified sarcosinates and lactylates to enhance antimicrobial effectiveness of ophthalmic compositions, particularly in the case where cationic preservatives otherwise bind to anionic polyelectrolytes.
  • the modified sarcosinates have the formula:
  • Representative modified sarcosinates include those sold under the Hamposyl ® trade name, such as lauroyl sarcosine (Hamposyl ® L), oleoyl sarcosine (Hamposyl ® O), myristoyl sarcosine (Hamposyl ® M), cocoyl sarcosine (Hamposyl ® C), stearoyl sarcosine (Hamposyl ® S), and pelargodoyl sarcosine (Hamposyl ® P).
  • Representative lactylates include sodium capryl lactylate (Pationic ® 122A). Additional solutions to the problem of cationic preservative - anionic polyelectrolyte binding problem in topically administrable pharmaceutical compositions are desirable.
  • Fatty acid/amino acid soaps are known and include, for example, those surfactants sold under the Aminosoap ® trade name (Ajinomoto Co., Inc., Tokyo, Japan). According to product brochures, Aminosoap ® surfactants are used in hair and body care (hair shampoo, body wash and bath foam), facial care (facial cleanser, facial washing foam, facial washing creme, and makeup remover), and household and health care.
  • Aminosoap ® surfactants are used in hair and body care (hair shampoo, body wash and bath foam), facial care (facial cleanser, facial washing foam, facial washing creme, and makeup remover), and household and health care.
  • the present invention provides a method of enhancing the preservative efficacy of topically administrable pharmaceutical compositions containing an anionic polyelectrolyte and a cationic preservative. According to the method of the present invention, a fatty acid/amino acid soap is added to the topically administrable pharmaceutical composition.
  • fatty acid/amino acid soaps to the compositions results in the release of the bound cationic preservative from the anionic polyelctrolyte by the formation of a loose and reversible surfactant-preservative complex.
  • the surfactant-preservative complex has antimicrobial effectiveness.
  • the soaps may themselves possess antimicrobial activity.
  • the fatty acid/amino acid soaps of the present invention improve the preservative efficacy of topically administrable pharmaceutical compositions. Accordingly, the present invention also relates to topically administrable pharmaceutical compositions containing one or more pharmaceutically active agents, an anionic polyelectrolyte, a cationic preservative, and a fatty acid/amino acid soap.
  • composition ingredients expressed in percentage terms are expressed as weight/weight.
  • Fatty acid/amino acid soaps useful in the preservative systems of the present invention are those wherein the fatty acid component is derived from a C 8 - C 24 fatty acid and the amino acid component is selected from the group consisting of lysine and arginine.
  • the fatty acid component is selected from the group consisting of cocoyl, linoleoyl, lauroyl, myristoyl, stearoyl, oleoyl, and pelargodoyl fatty acid residues.
  • Such fatty acid/amino acid soaps are commercially available or can be made by known methods.
  • the soap where the fatty acid component is cocoyl and the amino acid component is derived from arginine is commercially available as
  • AMINOSOAP AR-12 from Ajinomoto Co., Inc. (Tokyo, Japan).
  • the soap where the fatty acid component is cocoyl and the amino acid component is derived from lysine is available as AMINOSOAP LYC-12.
  • the amount of fatty acid/amino acid soap present in the compositions of the present invention is from about 0.001 to about 1 %, preferably from about 0.01 to about 0.2%, and most preferably from about 0.03 to about 0.12%.
  • concentration of the fatty acid/amino acid soap should not be so high that it causes severe discomfort.
  • compositions of the present invention contain cationic antimicrobials and anionic polyelectrolytes.
  • Cationic antimicrobials are known in the art and include, but are not limited to, quaternary ammonium compounds, such as benzalkonium chloride and polyquaternium-1.
  • Anionic polyelectrolytes include high molecular weight, anionic mucomimetic polymers (e.g., carboxyvinyl polymers such as Carbopol ® ), polystyrene sulfonic acid polymers, cationic exchange resins (e.g., Amberlite ® or Dowex ® ), and the like.
  • High molecular weight, anionic mucomimetic polymers have a molecular weight between about 50,000 and 6 million.
  • the polymers are characterized as having carboxylic acid functional groups and preferably contain between 2 and 7 carbon atoms per functional group.
  • Suitable high molecular weight, anionic polymers are carboxyvinyl polymers, preferably those called Carbomers, e.g., Carbopol ® (B.F. Goodrich Co., Cleveland, Ohio). Specifically preferred are Carbopol ® 934P, Carbopol ® 974P and Carbopol ® 940.
  • Suitable high molecular weight, anionic polymers include: alginates, carrageenans, natural gums (xanthan, karaya and tragacanth) and carboxy methyl cellulose. Such polymers will typically be employed in an amount between about 0.05 and about 6%, depending on the desired viscosity of the composition.
  • Pourable liquid compositions generally comprise an amount of the polymer between about 0.05 and about 2%.
  • Cation exchange resins are characterized as either strongly acidic, such as those having sulfonic acid or sulfuric acid functionality, or weakly acidic, such as those having carboxylic acid functionality. Such resins are readily available, for example, from Rohm & Haas (Philadelphia,
  • the average particle size of the commercially available forms of the resins is about 40 to 150 microns.
  • the particle size of the resin is critical for topically administrable ophthalmic compositions. Accordingly, for topically administrable ophthalmic compositions, commercially available resin particles are reduced by known techniques, including ball milling, to a particle size of about 20 ⁇ m or less such that the average particle size is ⁇ 10 ⁇ m, and are preferably reduced to a particle size of about 10 ⁇ m or less. Ion exchange resins are typically used in an amount from about 0.05 to about 10%. Anionic mucomimetic polymers and cation exchange resins are discussed in greater detail in U.S. 4,911 ,920 issued March 27, 1990, the entire contents of which are hereby incorporated by reference herein.
  • polystyrene sulfonic acid polymers (and their salts) useful in the compositions of the present invention comprise the following repeating unit:
  • the active ingredient or ingredients that can be included in the compositions of the present invention include all ophthalmic, dermatological, otic or nasal agents that can be topically applied.
  • ophthalmic agents include (but are not limited to): anti-glaucoma agents, such as beta-blockers (e.g., betaxolol and timolol), muscarinics (e.g., pilocarpine), prostaglandins, carbonic anhydrase inhibitors (e.g., acetazolamide, methazolamide and ethoxzolamide), dopaminergic agonists and antagonists, and alpha adrenergic receptor agonists, such as para-amino clonidine (also known as apraclonidine) and brimonidine; anti-infectives, such as ciprofloxacin; non-steroidal and steroidal anti-inflammatories, such as suprofen, ketorolac, dexamethasone,
  • compositions of the present invention can also include other components, for example, pharmaceutically acceptable buffers; tonicity agents; comfort-enhancing agents; solubilizing aids; pH adjusting agents; antioxidants; and stabilizing agents.
  • the compositions may also contain additional preservatives (in conjunction with the cationic preservatives addressed above).
  • the compositions may be formulated in various dosage forms suitable for topical delivery, including solutions, suspensions, emulsions, and gels.
  • Betaxolol HCI 0.28 Amberlite IRP-69 0.25 Carbopol 974P 0.45 Cocoyl N-Lysine * 0.03 Boric Acid 0.4 Mannitol 4.5
  • 0.42g betaxolol hydrochloride, 0.375g amberlite IRP 69 resin, 0.60g boric acid, 6.75g mannitol, 0.015g disodium EDTA were combined in 40ml_ water and stirred for 30 minutes.
  • the pH of the formulation was adjusted to 6.5 by the addition of 2.2ml_ of 5N NaOH and the final batch amount was brought to 150ml_ with water.
  • the formulation was sterilized for 60 minutes in an autoclave oven at 121°C.
  • Betaxolol HCI 0.28 Amberlite IRP-69 0.25 Carbopol 974P 0.45 Cocoyl N-Lysine* 0.03 Boric Acid 0.4 Mannitol 4.5
  • Example 2 To the formulation was added 0.3g of 30% cocoyl lysine solution (Aminosoap LYC-12 from Ajinomoto). The formulation was adjusted to pH 6.5 by the dropwise addition of 10% tromethamine solution, and the final batch amount was then adjusted to 300g by the addition of water. The formulation was steam sterilized for 60 minutes at 121°C in an autoclave oven. The formulation of Example 2 was found to have the following characteristics.
  • Betaxolol HCI 0.28 Amberlite IRP-69 0.25 Carbopol 974P 0.45 Cocoyl N-Arginine* 0.03 Boric Acid 0.4 Mannitol 4.15
  • Antimicrobial preservative effectiveness was determined using an organism challenge test according to the methods described in the United States Pharmacopeia (USP) and European Pharmacopoeia (Ph.Eur.). Samples were inoculated with known levels of one or more of the following: gram-positive (Staphylococcus aureus ATCC 6538) and gram-negative (Pseudomonas aeruginosa ATCC 9027 and Escherichia coli ATCC 8739) vegetative bacteria, yeast (Candida albicans ATCC 10231 ) and mold (Aspergillus niger ATCC 16404).
  • the samples were then pulled at specified intervals to determine if the antimicrobial preservative system was capable of killing or inhibiting the propagation of organisms purposely introduced into the formulation.
  • the rate or level of antimicrobial activity determined compliance with the USP and/or Ph.Eur. preservative efficacy standards for ophthalmic preparations.
  • the compendial preservative standards for ophthalmic preparations are presented below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des savons d'acide gras ou d'acide aminé qui sont utilisés pour améliorer l'efficacité anti-microbienne de compositions pharmaceutiques topiques, compositions contenant au moins un principe actif, un conservateur cationique et un polyélectrolyte anionique, tel que des polymères carboxyvinyliques, de la gomme xanthane, des polymères d'acide polystyrène sulfonique et des résines échangeuses cationiques.
EP00961722A 1999-09-21 2000-09-11 Utilisation de savons d'acide gras ou d'acide amine pour ameliorer l'efficacite anti-microbienne de compositions pharmaceutiques topiques Withdrawn EP1214094A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US399013 1982-07-16
US39901399A 1999-09-21 1999-09-21
PCT/US2000/024765 WO2001021209A1 (fr) 1999-09-21 2000-09-11 Utilisation de savons d'acide gras ou d'acide amine pour ameliorer l'efficacite anti-microbienne de compositions pharmaceutiques topiques

Publications (1)

Publication Number Publication Date
EP1214094A1 true EP1214094A1 (fr) 2002-06-19

Family

ID=23577764

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00961722A Withdrawn EP1214094A1 (fr) 1999-09-21 2000-09-11 Utilisation de savons d'acide gras ou d'acide amine pour ameliorer l'efficacite anti-microbienne de compositions pharmaceutiques topiques

Country Status (10)

Country Link
EP (1) EP1214094A1 (fr)
JP (1) JP2003509474A (fr)
CN (1) CN1374874A (fr)
AR (1) AR025713A1 (fr)
AU (1) AU7363700A (fr)
BR (1) BR0014117A (fr)
CA (1) CA2391976A1 (fr)
PL (1) PL354365A1 (fr)
TR (1) TR200200724T2 (fr)
WO (1) WO2001021209A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444710B1 (en) 1998-10-27 2002-09-03 Alcon Manufacturing, Ltd. Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
FR2837710B1 (fr) * 2002-03-26 2005-07-08 Innovations Pharma Ag Composition topique a base de resines echangeuses d'ions, notamment pour le traitement des erythemes
EP2497460A1 (fr) * 2005-03-10 2012-09-12 3M Innovative Properties Co. Procédés de réduction de contamination microbienne
JP5870459B2 (ja) * 2010-08-27 2016-03-01 わかもと製薬株式会社 点眼用水性組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4209722C3 (de) * 1992-03-25 1997-06-19 Medproject Pharma Entwicklungs Tropfbares Gel für die Augenheilkunde
US5520920A (en) * 1992-08-28 1996-05-28 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5504113A (en) * 1994-03-02 1996-04-02 Allergan, Inc. Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug
JPH0977725A (ja) * 1995-09-13 1997-03-25 Ajinomoto Co Inc 脂肪酸リジン塩の製造方法
DK1124535T3 (da) * 1998-10-27 2003-01-06 Alcon Lab Inc Konserverende system til topisk indgivelige farmaceutiske præparater indeholdende en fedtsyre/aminosyresæbe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0121209A1 *

Also Published As

Publication number Publication date
TR200200724T2 (tr) 2002-06-21
WO2001021209A1 (fr) 2001-03-29
JP2003509474A (ja) 2003-03-11
AR025713A1 (es) 2002-12-11
CN1374874A (zh) 2002-10-16
BR0014117A (pt) 2002-05-14
CA2391976A1 (fr) 2001-03-29
PL354365A1 (en) 2004-01-12
AU7363700A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
US6146622A (en) Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
AU758450B2 (en) Preservative system for topically administrable pharmaceutical compositions
EP1124535B1 (fr) Systeme conservateur contenant un savon a base d'acides gras/acides amines pour compositions pharmaceutiques a administration locale
AU666957B2 (en) Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5520920A (en) Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
CA2345466C (fr) Composition ophtalmique agreable, a liberation prolongee, et procede de therapie oculaire
US6444710B1 (en) Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
WO2001021209A1 (fr) Utilisation de savons d'acide gras ou d'acide amine pour ameliorer l'efficacite anti-microbienne de compositions pharmaceutiques topiques
ZA200201696B (en) Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions.
AU671374B2 (en) Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
MXPA01004190A (en) Preservative system for topically administrable pharmaceutical compositions
MXPA01004189A (en) Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020131

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030528